PhD, MD, or MBA with scientific and business expertise
8+ years in business or corporate development in biopharma
Experience managing the entire deal lifecycle from sourcing to structuring
Proven ability to lead cross-functional teams on multiple projects
Strong strategic judgment with independent, external representation
Competent in NPV modeling and forecasting with clear communication skills
Track record of scientific and commercial opportunity evaluation
Basic understanding of biopharma R&D and clinical development processes.
Responsibilities
Drive business development strategy for targeted protein degradation
Identify and close transactions with leading biopharma companies
Own transactions from initial opportunity through signature agreement
Coordinate cross-functional diligence teams
Prepare partnering materials including presentations and term sheets
Lead external opportunity evaluation processes
Develop financial analyses to support key business decisions
Negotiate and execute collaboration agreements and represent Kymera externally.
Benefits
Competitive compensation package with performance-driven pay
Eligibility for annual bonuses and equity participation
Comprehensive benefits to support employee well-being.
Full Job Description
How you'll make an impact:
Drive Kymera's business development strategy, positioning our targeted protein degradation platform and pipeline at the center of strategic partnerships.
Identify, evaluate, and close strategic transactions with leading biopharma companies- spanning both buy- and sell-side opportunities.
Own transactions end to end, from initial opportunity through signature agreement, working closely with R&D, legal, finance, and outside counsel.
Lead and coordinate cross-functional diligence teams.
Prepare high-quality partnering materials, including presentations, term sheets, valuation models to support transaction processes.
Lead search and evaluation processes for prioritized external opportunities.
Develop financial analyses, including forecasts, comparables, and NPV valuations, to inform critical decisions.
Lead negotiation and execution of collaboration agreements (licensing and collaboration agreements, SRAs, MTAs, and CDAs) in close partnership with internal and external council.
Represent Kymera in the industry, building relationships with BD counterparts at current and potential partner companies
Represent Kymera at partnering conferences and industry events (eg. JPM, BIO) to build and maintain relationships with potential partners and support S&E activity.
Skills and experience you'll bring:
An advanced degree - PhD, MD, or MBA - that reflects both scientific fluency and business acumen.
8+ years of experience in business development, corporate development, or strategy consulting in biopharma.
Experience across the full deal lifecycle: sourcing, diligence, negotiation, and structuring.
Demonstrated success working with cross-functional teams and managing multiple concurrent projects
Strong strategic judgment, the ability to work independently and represent Kymera externally
NPV modeling, forecasting, and comparables analysis with the ability to communicate results clearly.
A track record of evaluating opportunities from both a scientific and commercial perspective.
Working knowledge of biopharma R&D (experience with small molecules is a plus), clinical development, and regulatory pathways
Excellent negotiation, written, and presentation skills.
Compensation
Kymera offers a competitive compensation package that recognizes both results and capabilities through market-based, performance-driven pay.
The anticipated base salary range for this role is $195,000 - $330,000, with eligibility for annual bonus, equity participation, and comprehensive benefits.
Actual salary is based on a holistic evaluation of the specific role/level as well as each candidate's depth of experience and the capabilities they bring to the position.
About Kymera Therapeutics
Kymera Therapeutics is a clinical-stage biopharmaceutical company that is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. The company's proprietary targeted protein degradation platform, Pegasus, is designed to harness the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on undruggable and difficult-to-drug targets. Kymera's initial programs are focused on oncology and immunology, with a goal of delivering transformative therapies for patients with previously untreatable diseases. Kymera was founded in 2015 and is headquartered in Cambridge, MA.